To include your compound in the COVID-19 Resource Center, submit it here.

NICE recommends Opdivo for NSCLC through CDF

The U.K.'s NICE issued a final appraisal determination (FAD) recommending the use of Opdivo nivolumab from Bristol-Myers Squibb Co. (NYSE:BMY) to treat squamous and

Read the full 247 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE